Physician profile
Dudley Baker
NPI 1053364851
$3,769.75
in general payments reported to CMS, 2019-2025
38 companies · $361 in 2025
The $361 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $731 · 2020: $322 · 2021: $523 · 2022: $215 · 2023: $749 · 2024: $869 · 2025: $361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,979.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,978.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $545.12 | 2019-2025 | |
| Astellas Pharma US INC | $517.44 | 2019-2025 | Veozah, Myrbetriq |
| Caldera Medical, INC | $433.65 | 2023-2024 | Desara |
| Avion Pharmaceuticals | $245.74 | 2019-2023 | Balcoltra, NP Thyroid 60 |
| Exeltis, USA INC. | $239.50 | 2019-2025 | Slynd |
| Bayer Healthcare Pharmaceuticals INC. | $170.59 | 2019-2023 | |
| Pfizer INC. | $160.75 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $145.34 | 2023-2025 | Myfembree |
| Mayne Pharma Commercial LLC | $127.83 | 2021-2025 | |
| Biogen, INC. | $126.62 | 2021-2024 | Zurzuvae |
| Daiichi Sankyo INC. | $101.69 | 2019-2021 | |
| Axonics, INC. | $81.66 | 2024 | Axonics |
| Shield Therapeutics INC | $70.74 | 2023-2024 | Accrufer |
| Lupin INC. | $70.57 | 2019 | |
| Therapeuticsmd, INC. | $66.99 | 2019-2020 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aspira Women'S Health INC | $52.40 | 2019-2024 | Ova1 |
| Scynexis, INC. | $51.88 | 2021-2022 | |
| Hologic Sales and Service, LLC | $50.42 | 2019-2025 | Thinprep 2000 Processor, Fluent Fluid Management System |
| Mission Pharmacal Company | $44.22 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $42.01 | 2019-2023 | Gardasil 9 |
| Agile Therapeutics, INC. | $41.67 | 2023 | Twirla |
| Evofem Biosciences, INC. | $39.38 | 2021-2023 | Phexxi |
| Millicent US INC | $37.73 | 2023 | Intrarosa, Femring |
| Exact Sciences Corporation | $36.52 | 2024-2025 | Cologuard Collection Kit |
| Pacira Pharmaceuticals Incorporated | $28.34 | 2024 | Exparel |
| Ethicon US, LLC | $26.41 | 2025 | Enseal |
| Smith+Nephew, INC. | $25.26 | 2025 | Pico 7 |
| Allergan, INC. | $24.49 | 2019-2020 | |
| Olympus America INC. | $22.71 | 2019 | |
| Mimedx Group, INC. | $21.85 | 2025 | |
| Baxter Healthcare | $20.71 | 2024 | Perclot |
| Karl Storz Endoscopy-America | $20.44 | 2019 | |
| Organon LLC | $19.83 | 2024 | |
| Myovant Sciences INC. | $19.41 | 2021 | |
| Renovia INC | $16.31 | 2019 | |
| Amgen INC. | $12.44 | 2019 | |
| Teleflex LLC | $11.09 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dudley Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.